BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 21, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Velcade bortezomib: Phase III data

In an open-label Phase III trial in 511 previously untreated MM patients ineligible for stem cell transplantation, induction therapy with Velcade plus melphalan, prednisone and thalidomide followed by maintenance therapy with Velcade plus thalidomide (VMPT/VT) met the primary endpoint of significantly improving...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >